1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019

About CINV
CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.

The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

Technavio's analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

Covered in this report
The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.

Technavio's report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- EMEA

Key Vendors
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck & Co
- Tesaro

Other prominent vendors
- Acacia Pharma
- Aphios
- Barr Laboratories
- Baxter Healthcare
- Eisai
- Especificos Stendhal
- F.Hoffmann La Roche
- Mundipharma
- Mylan Pharmaceuticals
- OPKO Health
- Orchid Healthcare
- Otsuka Pharmaceutical
- ProStrakan
- Sandoz (Novartis)
- Solvay Pharmaceuticals
- Specialised Therapeutics Australia
- Sun Pharma
- Taiho Pharmaceutical
- Teva Pharmaceuticals

Market driver
- Increase in incidence and prevalence of cancer
- For a full, detailed list, view our report

Market challenge
- Complex physiology of CINV
- For a full, detailed list, view our report

Market trend
- Increased use of combination therapies
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019
PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Product profiles

Zofran

Aloxi/Onicit/Paloxi

Akynzeo

Emend

PART 06: Disease Overview

Understanding the disease

Pathophysiology

Types of CINV

Causes

Risk factors

Management

Economic burden

PART 07: Regulatory guidelines on CINV

PART 08: Pipeline analysis

PART 09: Market landscape

Market overview

Market size and forecast

CINV Drugs Market in US

Five forces analysis

PART 10: Market segmentation by ROA

Oral

Parenteral

Transdermal patch

PART 11: Market segmentation by onset of disease in CINV

Acute CINV

Delayed CINV

Anticipatory CINV

Breakthrough CINV

PART 12: Market segmentation by pharmacological class of drugs

5-HT3 Receptor Antagonists

NK-1 Receptor Antagonists

Corticosteroids

Dopamine Receptor Antagonists

Benzodiazepines

Cannabinoids

PART 13: Market segmentation by type of therapy

Monotherapy

Combination therapy

PART 14: Geographical segmentation

PART 15: Market drivers

PART 16: Impact of drivers

PART 17: Market challenges

PART 18: Impact of drivers and challenges

PART 19: Market trends

PART 20: Vendor landscape

Competitive Scenario

Market Share Analysis 2014

Other prominent vendors

PART 21: Key vendor analysis

GlaxoSmithKline

Helsinn

Heron

Merck and Co. Inc.

Tesaro

PART 22: Appendix

List of abbreviation



List of Exhibits:
Exhibit 01: Product offerings
Exhibit 02: Types of CINV
Exhibit 03: Causes of emesis
Exhibit 04: Chemotherapeutic agents related emetic risk
Exhibit 05: Management of CINV
Exhibit 06: Summary of regulatory guidelines by ASCO, ESMO, MASCC, and NCCN for CINV treatment
Exhibit 07: Global CINV drugs market: Pipeline portfolio
Exhibit 08: Global CINV drugs market 2014-2019 ($ millions)
Exhibit 09: CINV drugs market in US 2014-2019 ($ millions)
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global CINV drugs market by ROA
Exhibit 12: Global CINV drugs market segment by onset of disease
Exhibit 13: Global CINV drugs market segment by pharmacological class of drugs
Exhibit 14: Global CINV drugs market segment by type of therapy
Exhibit 15: Segmentation of Global CINV Drugs Market by Geography 2014
Exhibit 16: Drivers of global CINV drugs market
Exhibit 17: Impact of drivers
Exhibit 18: Challenges of global CINV drugs market
Exhibit 19: Impact of drivers and challenges
Exhibit 20: YoY growth and revenue of Emend 2011-2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 22: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 24: Helsinn: products
Exhibit 25: Helsinn: Key pipeline products
Exhibit 26: Helsinn: Geographical presence
Exhibit 27: Heron: Product Pipeline
Exhibit 28: Merck and Co. Inc.: Business segmentation by revenue 2013
Exhibit 29: Merck and Co. Inc.: Business segmentation by revenue 2012 and 2013 (US$ billions)
Exhibit 30: Merck and Co. Inc.: Sales by geography 2013
Exhibit 31: Tesaro : Product segmentation
Exhibit 32: Tesaro : Geographical presence

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.